Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc HMTXF


Primary Symbol: V.HEM

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Retains Stonegate Capital Partners for Investor Relations

Marketwired May 11, 2015

Hemostemix to Present at the 2015 Annual Meeting of the Clinical Trials Association in Israel

Marketwired April 20, 2015

Hemostemix Expands Clinical Trial for Critical Limb Ischemia (CLI) to Four Sites in South Africa, Treats First South African Participant

Marketwired March 19, 2015

Hemostemix Expands Clinical Trial for Treating Critical Limb Ischemia to the Peter Munk Cardiac Centre at Toronto General Hospital

Marketwired March 6, 2015

Hemostemix Names Dr. Hardean E. Achneck as Vice President of Clinical Research and Operations

Marketwired February 2, 2015

Hemostemix Names Gerald D. Brennan, Jr. to Board of Directors; Announces Management Title Change

Marketwired January 28, 2015

Hemostemix Inc.: Corporate Update

Marketwired January 12, 2015

Hemostemix and Technical Ventures Complete RTO Transaction

Marketwired November 26, 2014

Technical Ventures RX Corp. Closes Financings and Plan of Arrangement

Marketwired November 12, 2014

Technical Ventures RX Corp. and TheraVitae Inc. Announce Shareholder Approval of Plan of Arrangement

Marketwired November 7, 2014

Technical Ventures Announces Update to Short Form Offering and Private Placement

Marketwired October 16, 2014

Technical Ventures Files Amended and Restated Information Circular

Marketwired October 8, 2014

Technical Ventures Announces Elmar R. Burchardt, M.D., Ph.D., D.S. to be Appointed as Chief Executive Officer and Director of TheraVitae Inc.

Marketwired October 2, 2014

Technical Ventures Increases Financing and Reschedules Special Shareholders Meeting

Marketwired September 23, 2014

Technical Ventures Announces TSX Venture Exchange Conditional Acceptance of Short Form Offering Document

Marketwired September 11, 2014

Technical Ventures Receives TSXV Conditional Acceptance for its Qualifying Transaction

TheNewsWire September 4, 2014

Technical Ventures Announces Financing and Provides an Update on its Qualifying Transaction

TheNewsWire June 5, 2014

Technical Ventures provides an Update on its Qualifying Transaction

TheNewsWire March 10, 2014

Technical Ventures provides an Update on its Qualifying Transaction

TheNewsWire February 24, 2014

Technical Ventures Provides an Update on its Qualifying Transaction

Marketwired October 31, 2013